Y-mAbs Therapeutics Down 36% After Hours on FDA Advisory Panel Vote
October 28 2022 - 4:52PM
Dow Jones News
By Josh Beckerman
Y-mAbs Therapeutics Inc. shares fell 36% to $5.75 in after-hours
trading as a Food and Drug Administration advisory committee voted
16-to-0 that the company didn't provide sufficient evidence to
conclude that cancer drug omburtamab improves overall survival.
The company said it is "disappointed" and is "committed to
working closely with the FDA on their review" of its
application.
Y-mAbs shares fell 27% Wednesday and 20% Thursday, and rose 1%
on Friday morning before a trading halt. The FDA posted documents
in advance of the Friday committee meeting and said there was
"uncertainty" related to a clinical trial.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 28, 2022 16:37 ET (20:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024
